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Abstract
Background: There is currently lack of knowledge about sur-
vival trend analysis of thalassemia patients. Therefore, the aim of
the present study was to assess 5-, 10-, 20-, and 30-year survival
of thalassemia patients over a 20-year time period.
Methods: In this retrospective cohort study, we analysed the
data of 982 beta-thalassemia patients in Iran. Birth cohort and tra-
ditional cohort analyses were used to obtain the 5-, 10-, 20-, and
30-year survival rates in various time intervals between 1995 and
2016.
Results: Five and 10-year survival rates remained unchanged
since 1995-2016. Overall, 20- and 30-year survival rates were
lower in younger birth cohorts than older ones. A declining trend
was found in 20-year survival rate from 1995 to 2000 for all and
also for thalassemia major patients, but was stable from 2001 to
2016. In addition, there was a declining trend in 30-year survival
rate from 1995 to 2008 for all and also for thalassemia major
patients, but was an increased trend from 2009 to 2016.
Conclusion: Over the past two decades and in recent birth
cohorts, the 20- and 30-year survival rates has declined. In other
words, declining survival trends in the birth cohorts may be asso-
ciated with some different causes of mortality such as exposure to
the toxic effects of iron over time and the occurrence of disease-
related mortality.
Introduction
Thalassemia is considered as a public health challenge with an
annual number of 60,000 to 70,000 new cases and 18,000 deaths
worldwide.1 Thalassemia is also one of the common
hemoglobinopathies disorders occurring in Iran. Despite a signif-
icant improvement in the thalassemia prevention program (TPP)2
and treatment,3 it is estimated that over 300 new cases are annual-
ly occurred in Iran.4
Conducting an obvious knowledge about epidemiological sta-
tus of the disease such as incidence and survival trends can help
policymaker in different aspects. This information is essential for
the planning of control and prevention strategies, evaluating the
effectiveness of interventions, and services delivery systems.
Previous epidemiological studies conducted on survival anal-
ysis for thalassemia disease have reported a significant improve-
ment in the survival rate based on the comparison with other sim-
ilar studies.5,6 Although, a few studies have reported a significant
effect of birth cohort on the survival rate.7,8 To date, there is no
evaluation of the survival trend in thalassemia patients during the
past two decades, and it is unknown whether this survival trend is
increasing over time or not. Therefore, the aim of the present
study, which is the first in its kind and also is in line with the pur-
poses of Iran’s National Institute of Health Research,9 was to
assess whether overall and 5-, 10-, 20-, and 30-year survival rates
of thalassemia patients have improved over a 20-year time period.
Materials and Methods
A retrospective cohort study was conducted on enrolling 1003
beta-thalassemia (major, intermedia, and sickle cell) patients in
2016 in Shiraz, the southern Iran. The inclusion criteria were hav-
ing a definitive diagnosis of beta-thalassemia major. We have
excluded the sickle cell thalassemia (16 patients) and those with
missing data (5 patients) from the analysis (Figure 1). This study
was performed following approval by the Ethics Review
Committee of Shiraz University of Medical Sciences.
The Iranian TPP was established in 1997.10 There is a referral
Hospital with a document-based system in each county for treat-
ment services of the patients. Data were extracted from patients’
medical records using a comprehensive predetermined checklist,5
which the information including type of thalassemia, date of birth,
and date of death (if applicable) were used in this analysis.
We derived 5-, 10-, 20-, and 30-year survival rates (as the end-
points of this study) in various time intervals between 1995 and
2016. The survival time for the patients was considered as the
interval between the date of birth and the date of death or May 31
in each year during 1995-2016. The Cochran-Armitage test was
used for survival trend analysis. The Chi-square for trend test was
used to compare in survival trends by type of thalassemia. The
Significance for public health
A downward trend in the survival of thalassemia patients observed in this
study suggest a potential supports of the community which is related with
the quality of life and then improving the survival in the thalassemia
patients. Moreover, some different social and individual factors might influ-
ence the survival which it is suggested further research to investigate these
factors on the survival. 
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subjects were divided into four birth cohorts (1961-70, 1971-80,
1981-90, and 1991-2000) and 20-, and 30-year survival rates were
calculated in various time intervals between 1995 and 2016 for
each birth cohort.
Moreover, the Kaplan-Meier estimate and log-rank tests were
used to describe and compare overall survival based on different
birth cohorts (1970s and earlier, 1980s, 1990s, and 2000 to the pre-
sent) which birth cohort 1970s was considered to be the reference
group. All statistical analyses were done with 95% confidence
interval using Stata 11.2 (StataCorp. College Station, TX, USA).
Results
The data of 982 patients were identified. Of them, 704 (72%)
patients were beta thalassemia major and 227 patients died.
Table 1 shows trend of 30-year survival rates of the patients by
birth cohorts in the past two decades. Overall, 30-year survival rate
is lower in younger birth cohorts than older ones in 2010 to 2016
for which the survival data for three birth cohorts are available. In
other words, 30-year survival rate for birth cohort 1981-90 at year
2016 was 0.69 which for birth cohort 1961-70 at year 2016 was
0.882.
Trend of 20-year survival rates of the patients by birth cohorts
in the past two decades is shown in Table 2. In all investigated year
(calendar year), the 20-year survival rate slowly declined with
increasing birth cohort. For example, 20-yer survival rate for birth
cohort 1961-70, 1971-80, 1981-90, and 1991-2000 was 100, 95.2,
84.3, and 83.0%, respectively (Figure 2).
Five-, 10-, 20-, and 30-year survival estimates for all tha-
lassemia patients and by type of thalassemia disease obtained in
various time intervals are presented in Figure 3 and 4, respectively.
In the Figures, the 5-, and 10-year survival rates remained
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Table 1. Trend of 30-year survival rates of thalassemia patients by
birth cohorts in the past two decades, Iran.
Calendar year                                        Birth cohorts
                                        1961-70               1971-80        1981-90
1996                                                  1.00                                -                          -
1997                                                 0.926                               -                          -
1998                                                 0.862                               -                          -
1999                                                 0.875                               -                          -
2000                                                 0.882                           0.873                      -
2001                                                 0.882                           0.878                      -
2002                                                 0.882                           0.857                      -
2003                                                 0.882                           0.861                      -
2004                                                 0.882                           0.837                      -
2005                                                 0.882                           0.737                      -
2006                                                 0.882                           0.737                      -
2007                                                 0.882                           0.734                      -
2008                                                 0.882                           0.730                      -
2009                                                 0.882                           0.742                      -
2010                                                 0.882                           0.744                  0.628
2011                                                 0.882                           0.752                  0.630
2012                                                 0.882                           0.752                  0.644
2013                                                 0.882                           0.752                  0.641
2014                                                 0.882                           0.752                  0.661
2015                                                 0.882                           0.752                  0.679
2016                                                 0.882                           0.752                  0.690
Figure 1. Flowchart of this retrospective study.
Table 2. Trend of 20-year survival rates of thalassemia patients by
birth cohorts in the past two decades, Iran
Calendar year                                         Birth cohorts
                       1961-70         1971-80         1981-90        1991-2000
1996                            1.00                      1.00                         -                            -
1997                            1.00                     0.973                        -                            -
1998                            1.00                     0.954                        -                            -
1999                            1.00                     0.948                        -                            -
2000                            1.00                     0.952                     0.877                         -
2001                            1.00                     0.952                     0.813                         -
2002                            1.00                     0.952                     0.822                         -
2003                            1.00                     0.952                     0.836                         -
2004                            1.00                     0.952                     0.832                         -
2005                            1.00                     0.952                     0.838                         -
2006                            1.00                     0.952                     0.834                         -
2007                            1.00                     0.952                     0.835                         -
2008                            1.00                     0.952                     0.833                         -
2009                            1.00                     0.952                     0.837                         -
2010                            1.00                     0.952                     0.843                     0.830
2011                            1.00                     0.952                     0.846                     0.832
2012                            1.00                     0.952                     0.846                     0.835
2013                            1.00                     0.952                     0.846                     0.823
2014                            1.00                     0.952                     0.846                     0.829
2015                            1.00                     0.952                     0.846                     0.840
2016                            1.00                     0.952                     0.846                     0.846
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unchanged since 1995-2016. There was a declining trend in 20-
year survival rate from 1995 to 2000 for thalassemia major
patients, but was stable from 2001 to 2016. Also, a stable trend was
observed for 20-year survival rate in thalassemia intermedia
patients. In addition, there was a declining trend in 30-year sur-
vival rate from 1995 to 2008 for all and also for thalassemia major
patients, but was an increased trend from 2009 to 2016 for both
types of thalassemia.
Discussion
Based on data collected from a large thalassemia patients’
cohort, we found a new finding which was inconsistent with find-
ing from the previous survival studies worldwide. We found a
declining trend in the 20- and 30-year survival rates from both TM
and TI patients during 1995–2016. But, the 5- and 10-year survival
rates were stable during two past decades. In this study, birth
cohort effect was also investigated on the 20- and 30-year survival
rates. Our finding showed that older birth cohorts had a higher 20-
and 30-year survival rates.
The 20- and 30-year survival rates have decreased during two
past decades since 1995 for both TM and TI patients. The trend of
both 20- and 30-year survival rates had a sharp reduction before
2000. There are some reasons which could explain this finding.
After implementation of the thalassemia prevention program from
1997, the quality of healthcare services may be improved. On the
other hand, several reforms have been implemented to Iran’s health
system over the last three decades. For example, the establishment
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Figure 2. Kaplan-Meier survival curves for the thalassemia
patients enrolled in this study stratified by birth cohorts. 
Figure 3. Five-, 10-, 20-, and 30-year survival estimates for thalassemia patients obtained in various time intervals, Iran, 1995-2016.
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of the Family Physician Programme in 2005,11 and the Health
Sector Evolution Plan in 201412 which the purposes of them were
to improve the referral system and provide healthcare services in
rural and urban areas. These reforms could explain the stable trend
in the 20-year survival rate after 2000 and increased trend in 30-
year survival rate after 2008 (Figure 3).
The 20- and 30-year survival rates declined with increasing
birth cohort, which the birth cohort 1961-70 had better survival
rates than birth cohort 1971 to present. We found no similar study
for comparison. But the probable explanation for this is that older
patients that survive from bone marrow transplantation (BMT) had
very good chance of long term survival as they do not require
blood transfusion. Therefore, selection bias may be affected of this
finding. Another explanation is that in most previous survival stud-
ies, cohort data were cross-sectionally analysed to obtain the sur-
vival rate at the end of study period. In these studies, Kaplan-Meier
plots were used to compare different birth cohorts which are incon-
sistent with our findings based on birth cohort. Telfer et al.13 con-
ducted a study to identify factors associated with long time sur-
vival in thalassemia patients. They reported that improved survival
after year 2000 compared to 1999 and earlier was unexpected,
because, patients born before 1999 have more exposed to the toxic
effects of iron-chelation therapy and then have more vulnerable to
the heart failure. Other studies have reported that some factors
such as delay in registration of thalassemia patients in the disease
registration system,2,4 and delayed diagnosis of the patients14 may
affect the poor outcomes for thalassemia patients. Another study
conducted by Ladis et al.15 showed a higher survival rate for
patients born after 1975 compared to those born before. Wu et al.16
recently published a study to determine the survival rate and com-
plications in TM patients and fund an improved survival rate from
89.6% of the patients born before 1995 to 94.3% of those born
after 1995.
Based on the traditional Kaplan-Meier survival analysis, our
findings have also shown a significant difference among birth
cohorts (Figure 4). In other words, older birth cohorts had a higher
survival rate. This result is inconsistent with the results from other
survival studies.7,8,15 In a study with 1044 Greek thalassemia to
assess the survival rate compared to the general population,
authors found that birth cohort has a negative significant trend
towards past decades.8
Despite the growing success rate of thalassemia prevention
programs in the past two decades,2,17 questions remain as to why
the survival rate of the patients has declined. In our opinion, estab-
lishment a multicentre study could help to identify the underlying
causes of this finding.
The data used in our study have been extracted two times from
document-based database. First time for another objective,18 which
was approved by Fasa University of Medical Sciences (Grant No.
93188) and the second time for our purpose. Therefore, the quality
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Figure 4. Five-, 10-, 20-, and 30-year survival estimates by type of thalassemia disease obtained in various time intervals, Iran, 1995-
2016.
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and precision of the data was a significant strength of this study.
An important limitation of the study was the lack of causes of
death in the studied cohort. This information could have helped in
the better inference of the declining trend in the 20-and 30-year
survival rates.
Conclusions
Over the past two decades and in recent birth cohorts, the 20-
and 30-year survival rates has declined. In other words, declining
survival trends in the birth cohorts may be associated with some
different causes of mortality such as exposure to the toxic effects
of iron over time and the occurrence of disease-related mortality.
Moreover, some different social and individual factors might influ-
ence the declining trends which further research to investigate
these factors on the survival trend is suggested.
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